Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA

Vera Therapeutics

Vera Therapeutics clinical programs — 25 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA · NYSE Ticker
Company details
Status
Public
HQ
4539 Metropolitan Ct, Frederick, Maryland 21704, US
Founded
2018
Employees
9
Programs
25
Drugs
32
Patents
140
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Vera Therapeutics projects

25 ClinicalTrials.gov programs sponsored by Vera Therapeutics.

Vera Therapeutics has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

25 programs

Clinical programs

  1. Atacicept

    Vera Therapeutics

    Lupus Nephritis (LN)

    phase 3 small molecule terminated

    1 trial

  2. Atacicept

    Vera Therapeutics

    IgA Nephropathy

    phase 3 mab active

    1 trial

  3. Immune Globulin 10% Intravenous Solution

    Vera Therapeutics

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  4. VS-6766-301

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  5. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  6. Atacicept

    Vera Therapeutics

    IgA Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  7. Atacicept

    Vera Therapeutics

    IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders

    phase 2 small molecule active

    1 trial

  8. Atacicept

    Vera Therapeutics

    pMN

    phase 2 small molecule active

    1 trial

  9. Atacicept 150 mg

    Vera Therapeutics

    IgA Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  10. Atacicept Autoinjector Combination, Atacicept

    Vera Therapeutics

    Multiple Autoimmune Glomerular Diseases

    phase 2 small molecule active

    1 trial

  11. Atacicept Autoinjector Combination, Atacicept

    Vera Therapeutics

    Treatment of IgAN

    phase 2 small molecule active

    1 trial

  12. Capecitabine

    Vera Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  13. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  14. Herzuma

    Vera Therapeutics

    HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study

    phase 2 small molecule active

    1 trial

  15. MAU868

    Vera Therapeutics

    BK Virus Infection

    phase 2 small molecule completed

    1 trial

  16. NestaCell®

    Vera Therapeutics

    COVID-19 Pneumonia

    phase 2 mab completed

    1 trial

  17. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  18. riliprubart

    Vera Therapeutics

    Autoimmune haemolytic anaemia

    phase 1 small molecule active

    1 trial

  19. CYP2C19 genotyping

    Vera Therapeutics

    Myocardial Infarction

    approved gene therapy completed

    1 trial

  20. Experimental: Hyperslim

    Vera Therapeutics

    Venous Thromboembolism (VTE)

    approved other active

    1 trial

  21. Peginterferon alfa-2a

    Vera Therapeutics

    Hepatitis B, Chronic

    approved small molecule active

    1 trial

  22. Pregabalin

    Vera Therapeutics

    Pain, Postoperative

    approved small molecule completed

    1 trial

  23. Nitazoxanide Tablets

    Vera Therapeutics

    COVID-19

    small molecule completed

    1 trial

  24. P2Y12 antagonist monotherapy

    Vera Therapeutics

    Coronary Artery Disease

    small molecule completed

    1 trial

  25. Remifentanil

    Vera Therapeutics

    Postoperative Pain

    small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Vera Therapeutics have?

25 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.